Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study

被引：0
|
作者：
Wolin, Edward M. [1 ]
Fisher, George A., Jr. [2 ]
Kunz, Pamela L. [2 ]
Liyanage, Nilani [3 ]
Lowenthal, Susan Pitman [4 ]
Mirakhur, Beloo [4 ]
Pommier, Rodney F. [5 ]
Shaheen, Montaser [6 ]
Vinik, Aaron [7 ]
机构：
[1] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[3] Ipsen Biopharmaceut Inc, Boulogne, France
[4] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[5] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[6] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[7] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷
关键词：
D O I：
10.14309/00000434-201610001-01076
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1076
引用
收藏
页码：S468 / S468
页数：1
相关论文
共 50 条
  • [1] Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT
    Wolin, E. M.
    Fisher, G. A.
    Kunz, P. L.
    Liyanage, N.
    Lowenthal, S. P.
    Mirakhur, B.
    Pommier, R. F.
    Shaheen, M.
    Vinik, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Lanreotide Depot/Autogel (LAN) Vs. Placebo (PBO) for Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs): Subgroup Analysis of the ELECT Study
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 10 - 11
  • [3] Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda
    Fisher, George A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
    Fisher, G. A., Jr.
    Wolin, E.
    Kunz, P. L.
    Liyanage, N.
    Mirakhur, B.
    Lowenthal, S. Pitman
    Pommier, R. F.
    Shaheen, M.
    Vinik, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study
    Fisher, George A., Jr.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Mirakhur, Beloo
    Lowenthal, Susan Pitman
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S457 - S458
  • [6] ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [7] Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) With Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients With Carcinoid Syndrome (CS): Results From the SymNET Study
    Ruszniewski, Philippe
    Caplin, Martyn E.
    Valle, Juan W.
    Lombard-Bohas, Catherine
    Poston, Graeme
    Perros, Petros
    Holubec, Lubos
    Delle Fave, Gianfranco
    Smith, Denis
    Niccoli, Patricia
    Maisonobe, Pascal
    Gomez-Panzani, Edda
    [J]. PANCREAS, 2015, 44 (02) : 357 - 358
  • [8] Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study.
    Pommier, Rodney F.
    Fisher, George A.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Lowenthal, Susan W. Pitman
    Mirakhur, Beloo
    Shaheen, Montaser F.
    Vinik, Aaron
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [9] Patient-Reported Satisfaction with Diarrhea Control Associated with Lanreotide Autogel/Depot (LAN) Treatment for Carcinoid Syndrome (CS) Is High in Gastroenteropancreatic Neuroendocrine Tumor (NET) Patients
    Ruszniewski, Philippe
    Caplin, Marlyn E.
    Valle, Juan
    Lombard-Bohas, Catherine
    Poston, Graeme
    Perros, Petros
    Holubec, Lubo
    Delle Fave, Gianfranco
    Smith, Denis
    Niccoli, Patricia
    Maisonobe, Pascal
    Massien, Christine
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [10] Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.
    Fisher, George A.
    Pommier, Rodney F.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Lowenthal, Susan W. Pitman
    Mirakhur, Beloo
    Shaheen, Montaser F.
    Vinik, Aaron
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345